Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
2. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
3. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
4. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
6. Cancer vaccines
- Dr. Elias Sayour
-
7. The regulation of cell therapy
- Prof. Moutih Rafei
-
8. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
9. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
10. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
11. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
12. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
13. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
14. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
15. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
17. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
18. MassBank development and future
- Dr. Emma L. Schymanski
-
19. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
20. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
21. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
22. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
23. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
25. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
26. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
-
27. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
29. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
30. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
31. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
32. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
33. Combating the HIV epidemic
- Prof. William Blattner
-
34. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
35. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
36. Pediatric cancer testing
- Prof. Joshua Schiffman
-
37. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
38. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
39. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
40. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
Topics Covered
- The process of preregistration and registered reporting in scientific publications
- Impact on research transparency and credibility
- Promoting interdisciplinary work
- Common misconceptions
Biography
Biography will be added shortly
Links
Series:
Categories:
External Links
Talk Citation
Ernst-Rasmussen, P.B. (2025, March 31). The role of preregistration and registered reports in improving research transparency and reproducibility [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 3, 2025, from https://doi.org/10.69645/BXQA6966.Export Citation (RIS)
Publication History
- Published on March 31, 2025
Financial Disclosures
- Dr. Peter Bonde Ernst-Rasmussen has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
The role of preregistration and registered reports in improving research transparency and reproducibility
Published on March 31, 2025
21 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Dr.
Peter Rasmussen,
thank you for joining us today.
In this interview, we
would like to discuss
preregistration and
registered reports as
a framework to improve
transparency and credibility
in scientific research.
You and your colleagues at
the Editorial Board of the Journal of
Experimental Physiology recently marked
the first registered report
in the field of physiology to
have both its protocol and its results
published in the same journal.
Could you begin by explaining
the process of
preregistration and
registered reporting in
scientific publications?
Dr. Ernst-Rasmussen:
Yes, certainly.
There are two steps
to the process.
One is preregistration and
one is the registered reporting.
The definition of the
preregistration is that
it needs to publish
a detailed research
plan of the study,
that includes the hypothesis,
the methodology, and
the analysis plan.
All those points that
you typically report before
the data collection begins.
You can do that
in multiple ways.
There are platforms out there as
we mentioned in the paper,
like OSF AsPredicted,
and if you're running
a larger study,
you can also do this
at clinicaltrials.gov.
As I mentioned,
the components are
hypothesis, design,
how you collect your data,
and what analysis
you have planned.
The idea of doing that is that
then you have the possibility,
later on in the whole process,
to distinguish between
what has been hypothesized
and tested a priori and
Hide